Newsroom



News

PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.



  • May 3, 2016
  • Pediatric research: Researchers now think fibrosis can be reversed
  • (The Columbus Dispatch) Fibrosis, one of the most devastating consequences of hundreds of human diseases, has long been thought by biomedical science to be fixed and irreversible.
  •   
  • PAH Is Rising in Elderly, and So Are Challenges in Correctly Diagnosing and Treating Their Disease
  • (Pulmonary Hypertension News) Elderly people at increased risk of pulmonary hypertension (PH) are increasingly also being diagnosed with pulmonary arterial hypertension (PAH). Diagnosis and management in this group can be quite challenging, and a report from Geneva University Hospitals suggested that all elderly patients with suspected PAH should be referred to an expert center for proper diagnosis and treatment of a disease that can have devastating consequences.
  •   
  • May 2, 2016
  • Scientists Discover Shared Genes in COPD and IPF, Pointing to Potential Drug Development
  • (Lung Disease News) Despite sharing some risk factors, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are usually studied in isolation, and the presence of possible shared molecular mechanisms has been unknown.
  •   
  • Special training strengthens heart of patients with pulmonary hypertension: study
  • (Shanghai Daily) A customized exercise program for patients with pulmonary hypertension could improve their oxygen uptake and heart strength, said a study of University Hospital Heidelberg on Wednesday. 
  •   
  • May 1, 2016
  • Yoga Shows Promise as Way to Improve Quality of Life in Pulmonary Arterial Hypertension (PAH) Patients
  • (Globe Newswire) WASHINGTON, April 28, 2016 (GLOBE NEWSWIRE) -- Today at the 36th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions, researchers from the Universities of Calgary and Alberta in Canada presented findings from a study testing the effects of Iyengar Yoga (IY) on patients suffering from varying stages of Pulmonary Arterial Hypertension (PAH). The study was aimed at determining if two-hour IY sessions over 12 weeks would improve health-related quality of life, particularly in patients suffering anxiety and depression.
  •   
  • Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness
  • (PubMed) The objective of this therapeutic review is to conduct a systematic review to assess the comparative efficacy and safety and to determine the cost-effectiveness of drug therapies for the treatment of PAH in adults.
  •   
  • April 30, 2016
  • Gene therapy halts pulmonary hypertension progression in large animal pre-clinical study
  • (Medical Xpress) Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School of Medicine at Mount Sinai. The study was published online this week, and will appear in the May 3 issue of the Journal of the American College of Cardiology (JACC). 
  •   
  • TGA approves combination treatment for PAH treatment
  • (The Pharma Letter) Australian regulator the Therapeutic Goods Administration (TGA) has approved a variation to expand the current therapeutic indication for Volibris (ambrisentan) to include its use in combination treatment with tadalafil for patients with pulmonary arterial hypertension (PAH) in Australia.
  •   
  • April 29, 2016
  • Memorial Hermann Heart & Vascular Institute-Texas Medical Center Launches Lung Transplant Program
  • (PR Newswire) Memorial Hermann-Texas Medical Center (TMC) is now offering lung transplants, establishing its reputation as an elite health center with a comprehensive transplant program covering all solid organs including kidney, liver and heart transplants.
  •   
  • April 28, 2016
  • Minimally important dyspnoea, fatigue changes in PAH patients defined
  • (News Medical) Researchers say that a change of around 1 unit in Borg dyspnoea or fatigue scores signifies an important change in patients with pulmonary arterial hypertension (PAH)
  •   
  • April 27, 2016
  • Pulmonary Fibrosis Foundation Patient Registry
  • (Pulmonary Fibrosis Foundation) The PFF Patient Registry is a collaborative effort that brings together multiple stakeholders including patients, health care providers, and researchers. The aim of the Registry is to advance research and improve the quality of life of patients with pulmonary fibrosis.
  •   
  • April 26, 2016
  • Karos Pharmaceuticals Advances Development of KAR5585 to Treat Pulmonary Arterial Hypertension into the Clinic
  • (Business Wire) Karos Pharmaceuticals, a privately held, clinical-stage biopharmaceutical company focused on orphan indications, including fibrotic, inflammatory, and metabolic diseases, announced that the Company has advanced its small molecule drug candidate, KAR5585, into the clinic. KAR5585 is being developed for the treatment of pulmonary arterial hypertension (PAH) and other rare diseases marked by extensive fibrosis. KAR5585 is a first-in-class, selective inhibitor of tryptophan hydroxylase 1 (TPH1) designed to reduce peripheral serotonin (5-HT) and 5-HT-associated vascular remodeling and fibrosis that are the hallmarks of PAH.
  •   
  • April 25, 2016
  • Balloon Angioplasty Seen to Benefit People with Inoperable CTEPH and Other Conditions, Too
  • (Pulmonary Hypertension News) Balloon pulmonary angioplasty (BPA) appears to be of multiple benefit to patients with chronic thromboembolic pulmonary hypertension (CTEPH), both in terms of hemodynamics and in other systemic disorders like glycemic control and kidney disease, according to a study published in the journal Circulation, titled “Multiple Beneficial Effects of Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension.”
  •   
  • COPD Raises Mortality Risk in CKD Patients
  • (Renal and Urology News) As for possible explanations for the increased risk for overall mortality and respiratory deaths among CKD patients, Dr Navaneethan and colleagues pointed out that “higher infection-related deaths, especially with pneumonia, have been reported in the CKD population.” The additional presence of COPD, they noted, could further increase the risk for pneumonia or other infection due to immunosuppression from long-term use of COPD medications. Further, they stated that “COPD is a known contributor to pulmonary hypertension and could contribute to adverse outcomes in CKD.”
  •   
  • April 24, 2016
  • Ion Transporter May Contribute to PAH Vascular Remodeling in
  • (Pulmonary Hypertension News) A study from Johns Hopkins School of Medicine showed that a cellular ion transporter might contribute to the increased expansion and migration of smooth muscle cells lining lung arteries in a model of pulmonary arterial hypertension (PAH). The findings provide new insights into disease mechanisms leading to blood vessel remodeling in PAH.
  •   
  • April 23, 2016
  • Inhaled pulmonary vasodilators for persistent pulmonary hypertension of the newborn: safety issues relating to drug administration and delivery devices
  • (Dove Press) Abstract: Treatment for persistent pulmonary hypertension of the newborn (PPHN) aims to reduce pulmonary vascular resistance while maintaining systemic vascular resistance. Selective pulmonary vasodilation may be achieved by targeting pulmonary-specific pathways or by delivering vasodilators directly to the lungs.
  •   
  • Praxair gets Canadian approval for sale of Noxivent nitric oxide
  • (Chemical Technology) Praxair Canada's Noxivent inhaled nitric oxide, in conjunction with ventilatory support and other appropriate agents, is indicated to treat term and late pre-term (=34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension.
  •   
  • April 22, 2016
  • In Rare Case, Pulmonary Hypertension Linked to Sarcoidosis Is Traced to Silica Dust Exposure
  • (Pulmonary Hypertension News) A study recently published in the journal European Respiratory Review reported the case of a man with pulmonary hypertension resulting from silica exposure-induced sarcoidosis. The report urges clinicians to be aware of this rare cause of pulmonary hypertension, in which specific analyses are needed to confirm a diagnosis.
  •   
  • April 21, 2016
  • Karos Pharmaceuticals Advances Development of KAR5585 to Treat Pulmonary Arterial Hypertension into the Clinic
  • (Business Wire) KAR5585 is a first-in-class, selective inhibitor of tryptophan hydroxylase 1 (TPH1) designed to reduce peripheral serotonin (5-HT) and 5-HT-associated vascular remodeling and fibrosis that are the hallmarks of PAH. 
  •   
  • Large Scleroderma Study Offers Genetic Map, Identifies Patients at Risk for Pulmonary Hypertension
  • (Scleroderma News) The imbalance and dysregulations that eventually lead to the onset of autoimmunity in scleroderma patients is still not fully known, but researchers theorize that a combination of environmental factors and genetic predisposition is at play.
  •   
  • April 20, 2016
  • Pulmonary Embolism and Pulmonary Hypertension in the Setting of Negative Computed Tomography
  • (Southwest Journal of Pulmonary & Critical Care) PAP can rise substantially in the acute or subacute setting, particularly when multiple disease processes are involved, and decrease to (near) baseline with proper therapy. Chronic PH may even be protective. In a complex clinical setting with multiple possible etiologies for elevated PAP, clinicians should have a high suspicion for PE despite a negative CTA.
  •   
  • New app helps patients with breathing disorder
  • (The Oxford Times) But the new app has a step-counter and GPS system so patients can do the test indoors or outside, with the results being sent directly to the hospital. 
  •   
  • INFORM: CTEPH underdiagnosed in patients with PE
  • (Healio) As many as 4% of patients with pulmonary embolism may develop chronic thromboembolic pulmonary hypertension, but imaging studies in patients with pulmonary embolism and a symptom of pulmonary hypertension are underutilized, according to new research published in the American Journal of Medicine. 
  •   
  • April 19, 2016
  • Development and Characterization of an Inducible Rat Model of Chronic Thromboembolic Pulmonary Hypertension
  • (AHA Journals - Hypertension) The current animal model seems suitable for detailed study of CTEPH pathophysiology and permits preclinical testing of new pharmacological therapies against CTEPH.
  •   
  • April 18, 2016
  • Pharmacokinetic Analysis of Drugs for Pediatric Pulmonary Hypertension.
  • (PubMed) This study demonstrates that oral dosing with bosentan and tadalafil in children may not achieve therapeutic blood concentrations. Thus, the optimal dosing must be established individually while monitoring blood drug levels.
  •   
  • April 17, 2016
  • CLINICAL CHARACTERISTICS AND DETERMINANTS OF EXERCISE-INDUCED PULMONARY HYPERTENSION IN PATIENTS WITH PRESERVED LEFT VENTRICULAR EJECTION FRACTION
  • (JACC) Recent studies have shown that exercise induced pulmonary hypertension (EIPH) is not rare in patients with preserved left ventricular ejection fraction (LVEF). However, determinants and clinical implication of EIPH in these subjects were unclear.
  •   
  • April 16, 2016
  • The WHO classification of pulmonary hypertension: A case-based imaging compendium
  • (The University of Chicago Press Journals) Pulmonary hypertension (PH) is defined as a resting mean pulmonary artery pressure greater than 25 mmHg. The World Health Organization (WHO) classifies PH into five categories. The WHO nomenclature assumes shared histology and pathophysiology within categories and implies category-specific treatment. Imaging of the heart and pulmonary vasculature is critical to assigning a patient’s PH syndrome to the correct WHO category and is also important in predicting outcomes. Imaging studies often reveal that the etiology of PH in a patient reflects contributions from several categories. Overlap between Categories 2 and 3 (left heart disease and lung disease) is particularly common, reflecting shared risk factors. Correct classification of PH patients requires the combination of standard imaging (chest roentgenograms, ventilation-perfusion scans, echocardiography, and the 12-lead electrocardiogram) and advanced imaging (computed tomography, cardiac magnetic resonance imaging, and positron emission tomography). Despite the value of imaging, cardiac catheterization remains the gold standard for quantification of hemodynamics and is required before initiation of PH-specific therapy. These cases illustrate the use of imaging in classifying patients into WHO PH Categories 1–5.
  •   
  • April 15, 2016
  • Why exercise beats bed rest for pulmonary hypertension patients
  • (UT Southwestern Medical Center) Patients who exercised experienced improvements in peak exercise heart rate and decreased blood pressure. In addition, patients who exercised also experienced improvements in a range of subjective measures of health status, including improvements in emotional health and mental health. But these findings do not mean that patients with pulmonary hypertension should dive into an exercise program on their own.  The doctor can help them determine how much exercise is appropriate and which activities will offer the most benefit.
  •   
  • April 14, 2016
  • Pulmonary hypertension
  • (The Lancet) The Lancet Respiratory Medicine has published a collection of Review papers discussing the burden and treatment of pulmonary hypertension, as well as several discussion pieces, to highlight the progress made in this important area. The renewed focus from pharmaceutical companies in this relatively rare condition with notable successes should be applauded. However, as the number of cases rise and the divide in access to effective treatment grows, pressure must be brought to bear upon stakeholders to improve the evidence base, and we hope this collection of content will help in this respect.
  •   
  • April 13, 2016
  • Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery
  • (Dovepress) These results highlighted the potentiality of optimized SLD nano-transfersomal films to enhance the transdermal permeation and the bioavailability of the drug with the possible consequence of reducing the dose and administration frequency.
  •   
  • FDA Rejects Medtronic’s Remodulin Pump
  • (Barchart) United Therapeutics' brief SEC filing didn't say why the FDA had rejected the device, and Medtronic has said nothing about it, although the FDA's response letter arrived over a week earlier. The filing did say that the letter had "noted various measures that Medtronic should take" to make the filing approvable, which the two companies were currently discussing.
  •   
  • April 12, 2016
  • New PH Biomarker and Non-Invasive Disease Detection Presented at ACC 2016
  • (Pulmonary Hypertension News) A scientist from the Montreal Heart Institute (MHI) recently presented the results of a Phase 2 clinical trial demonstrating PulmoBind biomarker’s safety and the PulmoBind tomography (SPECT) scan’s ability to detect abnormalities in pulmonary hypertension (PH) patients 
  •   
  • A World First at the Montreal Heart Institute - PulmoBind: A Biomarker for Diagnosing Pulmonary Hypertension
  • (Ottawa Citizen) During the annual meeting of the American College of Cardiology (ACC) in Chicago, a researcher from the Montreal Heart Institute (MHI) presented the results of a phase II clinical study demonstrating the safety of the PulmoBind biomarker and the ability of the PulmoBind tomography (SPECT) scan to clearly show abnormal results in patients with pulmonary hypertension.
  •   
  • April 11, 2016
  • Assessment of Thyroid Function in Idiopathic Pulmonary Hypertension
  • (PubMed) Idiopathic pulmonary hypertension (IPAH) is a rare, debilitating, and fatal disease. Late-onset treatment can lead to right heart failure, multiple organ damage, and death. Since the thyroid plays a major role in the metabolism and hemodynamics in humans, the screening of thyroid function is crucial. Thyroid dysfunction has been reported to cause pulmonary hypertension, but the thyroid is also involved in IPAH.
  •   
  • April 10, 2016
  • New Study Finds Thousands of Pulmonary Embolism Patients May Later Develop a Life-Threatening Form of Pulmonary Hypertension
  • (Sys-Con Media) "Between 300,000 and 600,000 Americans experience a pulmonary embolism every year, and our study shows that up to four percent of those patients may later go on to develop CTEPH," said Victor Tapson, M.D., director of the Venous Thromboembolism and Pulmonary Vascular Disease Research Program at Cedars-Sinai Medical Center in Los Angeles. "Furthermore, the results demonstrate that the risk of developing CTEPH after pulmonary embolism remains substantially under-recognized."
  •   
  • April 9, 2016
  • Uptravi for Treatment of PAH Gets Postive Opinion from EMA Committee; EC Decision Expected Soon
  • (Lung Disease News) Actelion recently announced in a press release that the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has reconsidered and re-adopted its positive opinion for the use of the oral selective IP prostacyclin receptor agonist Uptravi (selexipag) for the treatment of pulmonary arterial hypertension (PAH). Uptravi was originally discovered and developed by Nippon Shinyaku.
  •   
  • April 8, 2016
  • In PAH Patients, Study Finds Combo Therapy Reduces Risk of Clinical Worsening
  • (Lung Disease News) “Combining PAH-targeted therapies significantly reduced the risk of clinical worsening, as predefined in clinical studies, for patients with PAH. This effect was generally consistent across subgroups,” Annie Christine Lajoie, M.D., and her colleagues wrote in a press release from the Pulmonary Hypertension Research Group and Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center in Canada.
  •   
  • April 7, 2016
  • Eiger Bio's ubenimex an Orphan Drug in Europe for PAH
  • (Seeking Alpha) Ubenimex is an oral small molecule that inhibits two enzymes, aminopeptidase and leukotriene A4 hydrolase (LTA4H), the latter which plays an essential role in the formation of a pro-inflammatory mediator called LTB4 (leukotriene B4). It has been commercially available in Japan for over 25 years as an adjunct to chemotherapy, marketed by Nippon Kayaku under the brand name Bestatin. Eiger licensed it in November 2015 for PAH and other inflammatory disorders associated with LTB4.
  •   
  • April 5, 2016
  • Low Cardiac Index Seen to Predict Sleep Disordered Breathing in CTEPH Patients
  • (Pulmonary Hypertension News) CTEPH patients are burdened with chronic blood clots and remodeling of the pulmonary vasculature, leading to pulmonary hypertension associated with variable degrees of right ventricular dysfunction.
  •   
  • April 4, 2016
  • Pulmonary Rehab of Multiple Benefit to People with PH and Other Respiratory Diseases
  • (Pulmonary Hypertension News) Pulmonary rehabilitation has been shown to significantly improve the quality of life of those affected by lung diseases, including chronic obstructive pulmonary disease (COPD), interstitial pulmonary fibrosis (IPF), or pulmonary hypertension (PH), a University of Kentucky news release reported.
  •   

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives